Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 354 of 5804
-
New obesity drug HRS9531 takes on semaglutide in major trial
Disease control OngoingThis study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
Phase: PHASE3 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Ancient herbs meet modern medicine in new fertility trial for women with low egg reserve
Disease control Not yet recruitingThis study aims to evaluate the superiority of an integrated traditional Chinese and Western medicine regimen ("Xiehe DOR Bushen Tongzhi Formula" + ovulation induction therapy with ovulation monitoring and timed intercourse) compared to standard treatment alone (placebo + ovulati…
Phase: PHASE3 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New breast cancer trial adapts treatment based on early response
Disease control Recruiting nowThis prospective, response-guided phase II study investigates individualized neoadjuvant treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. After receiving neoadjuvant dual-HER2-targeted therapy with chemotherapy, …
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for tough esophageal cancers: triple therapy shows promise
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant toripalimab combined with chemotherapy and low-dose radiotherapy in patients with esophageal squamous cell carcinoma who are insensitive to neoadjuvant therapy. The main question it aims to answ…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could group MDMA therapy heal trauma from oct 7?
Symptom relief Recruiting nowThe goal of this clinical trial is to evaluate the safety, tolerability and effectiveness of group-based MDMA-assisted therapy compared to individual MDMA-assisted therapy in participants with PTSD, who were diagnosed following the events of 7 October 2023. The main questions it …
Phase: PHASE2 • Sponsor: Sheba Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New hope for lung scarring: TDI01 drug trial begins
Disease control Recruiting nowThis study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF). The study will be conducted in China and divided into two sta…
Phase: PHASE3 • Sponsor: Beijing Tide Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New RNA therapy aims to tame Out-of-Control immune system
Disease control Recruiting nowThis Phase 1, open-label study evaluates the safety, tolerability, and preliminary efficacy of RXIM002, a CD19-targeting circular RNA-mediated in-vivo CAR T-cell therapy, in adults with severe, relapsed, or refractory B cell-mediated autoimmune diseases.
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for tough pancreatic cancer: experimental combo tested
Disease control Recruiting nowThis Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed after first-line therapy.
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to shrink aggressive breast tumors before surgery
Disease control Recruiting nowThis study is a multicenter phase II trial planning to enroll 40 patients with primary triple-negative breast cancer (tumor size ≥2 cm, clinical lymph node stage cN0-3, M0). Participants will receive the combination therapy of Sac-TMT and KL-A167 during the neoadjuvant treatment …
Phase: PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Brain tumor patients may avoid seizures with simple drug
Prevention Recruiting nowThis is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which do…
Phase: PHASE2 • Sponsor: Ayal A. Aizer, MD • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
New hope for myeloma: experimental drug linvoseltamab faces off against standard care in major trial
Disease control Recruiting nowThis study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compar…
Phase: PHASE3 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy targets tough lung cancer gene
Disease control Not yet recruitingThis study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Targeted chemo infusion plus immunotherapy shows promise for tough liver cancer
Disease control Not yet recruitingThis trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC). Its primary objective is to evaluate the safety, tolerability, pharmacokinetic profiles, and …
Phase: PHASE1, PHASE2 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Spine disc injection could ease back pain without surgery
Disease control Recruiting nowThis is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration. The study will have a 52-week primary period followed by 52 week Follow-up Period (total of 104 weeks)…
Phase: PHASE3 • Sponsor: DiscGenics, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for bile duct cancer: targeted combo trial launches
Disease control Recruiting nowIn the present TACTIC clinical trial, the investigators propose to determine the clinical interest and immunological efficacy of a treatment combining MP0317 the FAP (Fibroblast Activation Protein)-dependent CD40 agonist, with anti-PD-L1(Programmed Death-Ligand 1) therapy (durval…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill aims to wipe out rare urinary tract cancer without surgery
Disease control Recruiting nowA Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Phase: PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Off-the-Shelf cell therapy takes aim at tough blood cancers
Disease control Not yet recruitingThis is a single-arm, open-label pilot study to evaluate the safety and efficacy of CD19-targeted allogenic CAR-T cells (19UCART) in patients with relapsed/refractory B-cell hematologic malignancies. 12 patients are planned to be enrolled in the dose-escalation trial. The primary…
Phase: PHASE1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo therapy targets lung cancer brain spread
Disease control Recruiting nowA Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal and Leptomeningeal Metastases
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo targets advanced colorectal cancer in major trial
Disease control Recruiting nowThis is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. "Rolling 6" design would be used to conduct dose escalation par…
Phase: PHASE1, PHASE2 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Gene therapy hopes to tame severe childhood epilepsy
Disease control Recruiting nowThis is an open-label, single-center study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of intrathecal RC001 in patients with Dravet syndrome aged 2 to 18 years. The study includes a dose-escalation part followed by a fixed dose treatment part,…
Phase: EARLY_PHASE1 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC